Literature DB >> 10887135

Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma.

D Jones1, C O'Hara, M D Kraus, A R Perez-Atayde, A Shahsafaei, L Wu, D M Dorfman.   

Abstract

Chemokine receptors mediate the migration of lymphocytes through the binding of soluble ligands, and their expression is differentially regulated in lymphocyte subsets. The pattern of chemokine receptor expression in T-cell non-Hodgkin lymphoma has not been previously studied. Using a panel of mouse monoclonal antibodies, we studied the immunohistochemical expression of the Th1-associated chemokine receptor CXCR3 in 141 patients with T-cell lymphoma, and we studied the receptors CCR4 and CCR5 and some of their ligands in a subset of these tumors. Expression of CXCR3 was typical of the smaller T cells in angioimmunoblastic lymphoma (15 of 18 patients), angiocentric lymphoma (3 of 3 patients), histiocyte-rich tumors (4 of 5 patients), and unspecified T-cell lymphomas (17 of 39 patients). CXCR3 expression was seen in only 1 of 15 patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphoma. In contrast, all ALK-positive tumors showed diffuse reactivity for the Th2-associated receptor CCR4 (5 of 5 patients). CCR4 expression was also a consistent feature of the large-cell transformation of mycosis fungoides. CCR5 expression showed no consistent association with any T-cell tumor type. The chemokines Mig (CXCR3 ligand), TARC (CCR4 ligand), and MCP-2 (CCR5 ligand) were detected in intratumoral blood vessels and histiocytes. Mig was also coexpressed by a subset of CXCR3-positive tumor cells in 6 of 20 lymphomas. MCP-2 was highly expressed in stromal cells in 3 patients with nodal involvement by cutaneous T-cell lymphoma. As with normal T-cell subsets, we demonstrated that there is frequent differential expression of chemokine receptors in T-cell tumors, which may explain, in part, the distinctive patterns of spread in different tumor subtypes. (Blood. 2000;96:685-690)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10887135

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

1.  Uncommon late relapse of angioimmunoblastic T-cell lymphoma after 16-year remission period.

Authors:  Edit Páyer; Zsófia Miltényi; Zsófia Simon; Lajos Szabados; Katalin Hegyi; Gábor Méhes; Arpád Illés
Journal:  Pathol Oncol Res       Date:  2011-11-30       Impact factor: 3.201

2.  Extranodal Marginal Zone Lymphoma-like Presentations of Angioimmunoblastic T-Cell Lymphoma: A T-Cell Lymphoma Masquerading as a B-Cell Lymphoproliferative Disorder.

Authors:  Benjamin Kaffenberger; Brad Haverkos; Kelly Tyler; Henry K Wong; Pierluigi Porcu; Alejandro Ariel Gru
Journal:  Am J Dermatopathol       Date:  2015-08       Impact factor: 1.533

3.  Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma.

Authors:  David M Dorfman; Julia A Brown; Aliakbar Shahsafaei; Gordon J Freeman
Journal:  Am J Surg Pathol       Date:  2006-07       Impact factor: 6.394

4.  Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma.

Authors:  Naoko Asano; Ritsuro Suzuki; Koichi Ohshima; Yoshitoyo Kagami; Fumihiro Ishida; Tadashi Yoshino; Hiroshi Ogawa; Yasuo Morishima; Shigeo Nakamura
Journal:  Int J Hematol       Date:  2010-03-09       Impact factor: 2.490

Review 5.  CXCR3 ligands: redundant, collaborative and antagonistic functions.

Authors:  Joanna R Groom; Andrew D Luster
Journal:  Immunol Cell Biol       Date:  2011-01-11       Impact factor: 5.126

6.  Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab.

Authors:  Xiao Ni; Timothy Langridge; Madeleine Duvic
Journal:  Oncoimmunology       Date:  2015-03-24       Impact factor: 8.110

7.  C-C chemokine receptor 4 expression in CD8+ cutaneous T-cell lymphomas and lymphoproliferative disorders, and its implications for diagnosis and treatment.

Authors:  Shamir Geller; Travis J Hollmann; Steven M Horwitz; Patricia L Myskowski; Melissa Pulitzer
Journal:  Histopathology       Date:  2019-11-13       Impact factor: 5.087

8.  Purification and biochemical characterization of the D6 chemokine receptor.

Authors:  Paul E Blackburn; Clare V Simpson; Robert J B Nibbs; Maureen O'Hara; Rhona Booth; Jemma Poulos; Neil W Isaacs; Gerard J Graham
Journal:  Biochem J       Date:  2004-04-15       Impact factor: 3.857

9.  PARC/CCL18 is a plasma CC chemokine with increased levels in childhood acute lymphoblastic leukemia.

Authors:  Sofie Struyf; Evemie Schutyser; Mieke Gouwy; Klara Gijsbers; Paul Proost; Yves Benoit; Ghislain Opdenakker; Jo Van Damme; Geneviève Laureys
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

10.  Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study.

Authors:  Kentaro Yonekura; Shigeru Kusumoto; Ilseung Choi; Nobuaki Nakano; Asahi Ito; Youko Suehiro; Yoshitaka Imaizumi; Makoto Yoshimitsu; Kisato Nosaka; Eiichi Ohtsuka; Michihiro Hidaka; Tatsuro Jo; Hidenori Sasaki; Yukiyoshi Moriuchi; Masao Ogata; Hiro Tatetsu; Kenji Ishitsuka; Yasushi Miyazaki; Ryuzo Ueda; Atae Utsunomiya; Takashi Ishida
Journal:  Blood Adv       Date:  2020-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.